Peginterferon beta-1a - Biocad

Drug Profile

Peginterferon beta-1a - Biocad

Alternative Names: BCD 054

Latest Information Update: 19 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Biocad
  • Class Interferons
  • Mechanism of Action Immunomodulators; Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis

Most Recent Events

  • 15 Apr 2016 Biocad plans a phase II trial for Multiple sclerosis in Russia (IM) (NCT02744222)
  • 01 Dec 2015 Biocad completes a phase I trial in Healthy volunteers in Russia (IM, SC) (NCT02359877)
  • 01 Jul 2014 Phase-I clinical trials in Multiple sclerosis (In volunteers) in Russia (IM, SC) (NCT02359877)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top